Skip to content

Efficacy and Safety of anterior versus posterior Transvaginal Sacrospinous Ligament Fixation (ANCORIS)

Prospective, Multicenter, Randomized Controlled Trial comparing Efficacy and Safety of anterior Sacrospinous Ligament Fixation with versus posterior Sacrospinous Ligament Fixation in Apical Prolapse Treatment - Ancoris Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON58425
Enrollment
156
Registered
2025-07-25
Start date
2025-12-01
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

(Apical) pelvic organ prolapse, vaginal vault prolapse, uterine prolapse, pelvic floor descent Prolapse of the uterus or vagina

Interventions

We compare posterior approach SSLF to anterior approach SSLF (both using the ANCORIS tissue achoring system). In both study groups, an additional anterior colporrhaphy is performed, as this is normal

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Subject is female;  Subject is least 18 years of age;  Subject has at least a stage 2 apical prolapse and is planned to undergo vaginal surgical correction due to symptomatic (presence of vaginal bulge sensation) apical pelvic organ prolapse.Both surgical approaches are considered to be technically feasible by the operating surgeon, based on clinical and anatomical evaluation

Exclusion criteria

Exclusion criteria: Subjects who are pregnant or want to become pregnant;  Subjects who are not capable of giving informed consent;  Subject has a known sensitivity to polypropylene;  Subject has an indication for a concomitant procedure to treat stress urinary incontinence (SUI);  Subject is known with pelvic organ cancer (e.g. uterine, ovarian, bladder or cervical);  Subject previously had, currently has, or is planned to have pelvic radiation therapy Subject has an active or latent infection of the vagina, cervix or uterus Subject has chronic systemic pain that includes the pelvic area or chronic focal pain that involves the pelvis;  Subject has a known neurologic or medical condition affecting bladder function (e.g. multiple sclerosis, spinal cord injury or stroke with residual neurologic deficit). 

Design outcomes

Primary

MeasureTime frame
The primary outcome measure will be surgical “success” or “failure” assessed one year after surgery. The primary outcome measure has three components: anatomic success; leading edge of apical vaginal wall at or above the hymen using POP-Q examination  the absence of vaginal bulge symptoms specific to prolapse, using two  questions from the PFDI; no re-treatment necessary in the treatment (surgical or non-surgical) of apical prolapse repair.  In both groups, an additional anterior colporrhaphy is added, as this is regular clinical practice. An additional perineoplasty may be added as well, if clinically indicated.  

Secondary

MeasureTime frame
To compare outcomes between anterior approach SSLF, and conventional posterior approach SSLF, at 6 weeks, 12 months, and 36 months using the following parameters:  Morbidity (Pain, ADL, hospital stay, surgical parameters, postoperative recovery, blood loss);  Quality of life: based on the Prolapse - Quality of Life (P-QoL) questionnaire, The Patient Global Impressions scale (PGI), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12), the Pelvic Floor Distress Inventory (PFDI-20) Estimated anatomical failure-free survival per Kaplan-Meier.  Procedure related serious adverse events including complications at follow-ups, as well as their classification per Clavien-Dindo and IUGA/ICS terminology Prolapse occurrence in the non-target compartment Intraoperative characteristics (surgical duration, surgical complexity as perceived by the surgeon) 

Countries

Netherlands

Contacts

Public ContactJ.P.W.R. Roovers

Amsterdam UMC

ancoris@amsterdamumc.nl0205669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 29, 2026